Overview

Drug-drug Interaction Study With TS-142 in Healthy Adult Subjects (Concomitant Administration of Itraconazole)

Status:
Completed
Trial end date:
2020-11-14
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center, single-sequence study to evaluate the concomitant effects of the potent CYP3A inhibitor itraconazole on the single-dose pharmakokinetics, safety and tolerability of oral TS-142 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Taisho Pharmaceutical Co., Ltd.
Treatments:
Itraconazole